Clean Science & Technology Ltd
Clean Science & Technology Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
HALS segment expected to continue growing quarter-on-quarter, with 25% volume growth already seen in Q2 and plans to increase capacity utilization and revenues over the next two quarters. HALS segment showing strong growth with 25% QoQ volume increase; expected to continue quarter-on-quarter growth, improving capacity utilization and revenues in next two quarters.
From Clean Science & Technology Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- HALS segment expected to continue growing quarter-on-quarter, with 25% volume growth already seen in Q2 and plans to increase capacity utilization and revenues over the next two quarters.
- Performance Chemicals Unit 1 capacity started with ~1,000 tons per annum, aiming for clearer customer demand next quarter before scaling further.
- Performance Chemicals Unit 2 facility scheduled to start water trials in April 2026 and commercial production by June 2026, with a 3-year ramp-up expected.
- The company targets INR 300 crore revenue from 10,000 tons capacity in Performance Chemicals by FY28.
- Domestic market (mainly HALS) grew 13% in H1 FY26; still room to expand customer base with 70-75% capacity utilization for food-grade antioxidants.
- Growth in new products and markets (US, Europe, Vietnam, Middle East, South Africa) expected as product acceptance improves.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Clean Science & Technology Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Clean Science invested approximately INR 150 crores in the subsidiary (CFCL) during H1 FY26.
- Performance Chemical 1 facility is undergoing chemical trials with commercialization expected within 3-4 weeks.
- Performance Chemical 2 facility water trials to start in April with commercial production anticipated by June; ramp-up expected over approximately 3 years.
- Capacity expansion of some food-grade antioxidants has been successfully completed.
- A new product (hydroxychloroquine-related) with an installed capacity of about 10,000 tons aims to generate approximately INR 300 crores revenue by FY28.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Clean Science & Technology Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has started commercial samples for Performance Chemical One with less than 1,000 tons per annum of existing capacity utilized through refurbishment.
- Full installed capacity for Performance Chemical One is about 10,000 tons, with revenue potential of around INR 300 crores by FY 2028.
- Commercialization of barbituric acid successfully completed by repurposing existing facilities.
- Capacity expansions have been done for some food-grade antioxidants.
- Sales for Performance Chemical One and barbituric acid expected to gather momentum with increasing approvals and validations over coming quarters.
- Sales volumes for HALS products growing sequentially at 25% volume and 34% value growth.
2 more points management made on order book & pipeline
Clean Science & Technology Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹249 Cr, net profit ₹58 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Clean Science & Technology Ltd's management said in earlier quarters
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Bodal Chemicals Ltd (Q2 FY26)
Q2 FY26 consolidated revenue from operations: Rs 4,804.5 mn, up 11.2% YoY from Rs 4,321.2 mn (Page 10). Key concall takeaways from Bodal Chemicals Ltd's Q2…
- Chemcon Speciality Chemicals Ltd (Q2 FY26)
Q2 FY26 revenue from operations: ₹53.7 crore, up 2% YoY (vs ₹52.6 crore in Q2 FY25) [Page 9, 6] . Key concall takeaways from Chemcon Speciality Chemicals Ltd's…
- Valiant Organics Ltd (Q2 FY26)
Q2-FY26 consolidated revenue from operations: INR 1,573 million, down 1.8% year-on-year (Page 12). Key concall takeaways from Valiant Organics Ltd's Q2 FY26…
- Indian Phosphate Ltd (Q2 FY26)
H1 FY 25-26 revenue increased by ~15% to ₹451 crores versus ₹385 crores in H1 FY 24-25. Key concall takeaways from Indian Phosphate's Q2 FY26 earnings call…
Frequently Asked Questions
What were Clean Science & Technology Ltd Q2 FY26 results?
HALS segment expected to continue growing quarter-on-quarter, with 25% volume growth already seen in Q2 and plans to increase capacity utilization and revenues over the next two quarters. HALS segment showing strong growth with 25% QoQ volume increase; expected to continue quarter-on-quarter growth, improving capacity utilization and revenues in next two quarters.
What is Clean Science & Technology Ltd share price analysis?
Clean Science & Technology Ltd currently shows a neutral. The stock trades at a P/E of 35.1 with a market cap of ₹8,173 Cr. Investors should review the full earnings analysis for detailed insights.
Is Clean Science & Technology Ltd planning capital expenditure?
Clean Science invested approximately INR 150 crores in the subsidiary (CFCL) during H1 FY26.
Keep Clean Science & Technology Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.